Clinical trials
Haploidentical Stem Cell Transplantation clinical trials
Below are recruiting haploidentical stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 105 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06158828RecruitingPhase 1/Phase 2
Natural Killer Cells After Half-Matched Stem Cell Transplant for High-Risk AML
This study tests a new way to prevent leukemia from returning after a half-matched stem cell transplant. It uses specially activated natural killer cells to attack remaining cancer cells. This may help people with high-risk or relapsed AML who have few other options.
St Louis, MissouriAges 18 years+ - NCT05011422RecruitingPhase 1
Stem cell transplant using half-matched donor for kids with blood cancer
This study tests a special stem cell transplant for children and young adults with certain high-risk blood cancers or bone marrow diseases. It uses a half-matched family donor and a technique to remove specific cells, which may lower the risk of side effects and help the body accept the new cells.
St Louis, MissouriAges Up to 30 years - NCT07246031RecruitingPhase 2
BPC2001 to Prevent Graft-Versus-Host Disease After Stem Cell Transplant
This trial tests a new drug, BPC2001, to see if it can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) in people receiving a half-matched stem cell transplant from a family donor. It may be an option for adults with certain blood cancers who are planning their first transplant.
Beijing, Beijing MunicipalityAges 18–65 - NCT06639854Recruiting
CMV immunity test to guide antiviral prevention after transplant
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
Houston, TexasAges 18 years+ - NCT06041893Recruiting
Stem cell transplant with gentler immune therapy
This trial offers a stem cell transplant from a half-matched (haploidentical) donor for children. It uses an early medicine to calm the immune system and a lower dose of a drug to prevent rejection and graft-versus-host disease.
SeoulAges Any age - NCT04022239RecruitingPhase 1/Phase 2
Bendamustine to prevent transplant immune complications
This early-phase study tests whether giving the drug bendamustine (with or without another chemo drug) can lower the risk of graft-versus-host disease (GVHD) after a stem cell transplant. GVHD is an immune reaction where the donor’s cells attack your body. If it works and is safe, it could improve outcomes after transplant.
Houston, TexasAges 18–70 - NCT07214688RecruitingPhase 2
Transplant Prep with Chemo, Radiation, and GVHD Prevention for Blood Cancers
This trial tests a standard transplant preparation (chemotherapy and low-dose radiation) followed by a special drug (PTCy) to prevent graft-versus-host disease after a donor stem cell transplant for blood cancers. It may help improve transplant success and reduce complications.
Washington D.C., District of ColumbiaAges 18–65 - NCT06512519Recruiting
Second stem cell transplant for graft failure
This trial tests a second transplant using a half-matched donor for people whose first transplant failed. It may help if you have a blood cancer and are otherwise healthy enough for another procedure.
Beijing, Beijing MunicipalityAges 14 years+ - NCT06075563Recruiting
Total Lymphoid Irradiation for Children's Stem Cell Transplant
This trial tests a special type of radiation (total lymphoid irradiation) as part of the preparation for a stem cell transplant from a half-matched donor. It aims to make the transplant safer and more effective for children who need a transplant but don't have a fully matched sibling donor.
Hong KongAges Up to 18 years - NCT06453460RecruitingPhase 2
Preventing CMV with letermovir after stem cell transplant
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
Orange, CaliforniaAges 18 years+ - NCT04187105RecruitingPhase 2
Total marrow radiation using a targeted intensity plan before transplant
This Phase 2 study tests a more precise type of whole bone-marrow radiation before a stem cell transplant. It may help patients with certain high-risk blood cancers by preparing the body for transplant more safely and effectively.
Chicago, IllinoisAges 18–75 - NCT06034535RecruitingPhase 2
A stem cell transplant trial using special donor cells
This trial tests a new way to give donor cells after a stem cell transplant to help the body accept them. It may help patients who need a transplant but don't have a perfectly matched donor.
Hong KongAges Up to 18 years - NCT07509450Recruiting
Fecal transplant study for CAR-T and stem cell transplant patients
This pilot study tests whether giving a fecal microbiota transplant before standard CAR-T therapy (for B-cell lymphoma) or reduced-intensity stem cell transplant (for AML or high-risk MDS) can improve treatment outcomes. It aims to see if restoring gut bacteria helps reduce complications.
Toronto, OntarioAges 18 years+ - NCT07244419RecruitingEarly Phase 1
Preventing stem cell transplant rejection in children
This early-phase trial tests a medication to prevent rejection of donated stem cells in children. It's for patients who are at high risk for their transplant to fail.
Cincinnati, OhioAges Any age - NCT07648992RecruitingPhase 4
ATG dosing strategy for unrelated donor stem cell transplant
This trial tests a personalized approach to using ATG (a medicine that reduces immune rejection) in patients receiving stem cell transplants from unrelated donors for blood cancers. The goal is to improve transplant success while reducing side effects by tailoring ATG doses to individual patients.
Beijing, Beijing MunicipalityAges 14–65 - NCT07719946RecruitingPhase 2
Lower dose chemo after stem cell transplant for blood cancers
This trial tests whether a lower dose of the chemotherapy drug cyclophosphamide given after a stem cell transplant is safe and effective for people with blood cancers. The goal is to reduce side effects while still helping prevent the cancer from coming back.
Navi Mumbai, MaharashtraAges 18 years+ - NCT03279094RecruitingPhase 1
Testing a half-matched bone marrow transplant for sickle cell
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
Duarte, CaliforniaAges 1–30 - NCT03850366RecruitingPhase 2
Haploidentical stem cell transplant with two post-transplant medicines
This trial tests a way to treat certain blood cancers using a stem cell transplant from a partially matched (haploidentical) donor. It aims to make the transplant safer and reduce the chance of the immune reaction that can follow transplant, using post-transplant cyclophosphamide and bortezomib.
Detroit, MichiganAges 18–65 - NCT04195633RecruitingPhase 2
Haploidentical donor stem cell transplant to treat blood cancers
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
Seattle, WashingtonAges 6 months+ - NCT04201210RecruitingPhase 2
Stem cell transplant study for young people with severe sickle cell
This Phase 2 study tests a type of stem cell transplant that uses donor immune cells that have been specially “tweaked” to help treat sickle cell disease. It may help prevent serious sickle cell complications, but it requires careful matching and screening of organs and pregnancy status.
ViennaAges 2–35 - NCT04370301RecruitingPhase 2
Reduced-intensity stem cell transplant with JAK inhibitor for myelofibrosis
This study tests giving a JAK inhibitor before and after a reduced-intensity stem cell transplant to treat primary or secondary myelofibrosis. The goal is to improve disease control while using a less harsh transplant approach.
Seattle, WashingtonAges 18–70 - NCT04375631RecruitingPhase 1
Study of chemo plus donor stem cell transplant for blood cancers
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
Seattle, WashingtonAges 18 years+ - NCT04678401RecruitingPhase 1
Trial tests transplant using a half-matched donor for high-risk leukemia
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
Boston, MassachusettsAges 18–75 - NCT05066412RecruitingPhase 1
Preventing relapse after a half-matched transplant with modified donor cells
This early-phase study tests whether giving donor immune cells (DLI) that have been “depleted” of a specific marker (CD45RA) can lower the chance of the leukemia/lymphoma coming back after a half-matched stem cell transplant. It’s meant to be preventive, not treatment for an active relapse.
Geneva, Canton of GenevaAges 18 years+
Hear when a new Haploidentical Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for haploidentical stem cell transplantation?
- Yes. Clin2 currently lists 105 recruiting haploidentical stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a haploidentical stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a haploidentical stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Haploidentical Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation
- Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.